Drug infusion technologies developer Innovative Health Sciences (IHS) has expanded its commercialisation team to support the marketing of the Insignis Syringe Infusion System.
Insignis System features a 13.5psi mechanical syringe driver and a selectable rate flow control device, designed for both intravenous and subcutaneous use.
The single, non-electric pump infusion device was cleared by the US Food and Drug Administration (FDA) on 01 March 2024. It secured CE mark certification in 2021.
According to New York-based IHS, the system offers affordable, effective, and convenient infusion options across various settings, including ambulatory care, hospitals, clinics, and home use.
The infusion technologies developer has appointed Justyn Okoniewski as sales vice president to drive business growth and commercialisation.
The system offers a new level of convenience, safety, innovation, and autonomy, empowering subcutaneous immunoglobulin (SCIg) patients to select, titrate, and adjust flow rates in real-time, IHS said.
By addressing the challenge of painful site reactions, the Insignis System improves the infusion therapy experience, helping patients reduce or even prevent common site issues.
Innovative Health Sciences founder and chairman Andrew Sealfon said: “With the FDA clearance for our unique approach to delivering medications, including the novel tapered flow technique, we’re on the cusp of shifting the paradigm in our field, making critical infusions more comfortable, affordable, and accessible than ever.
“I’m excited to welcome Justyn to the team where he will help lead IHS into the next phase of development and growth.”
The newly FDA-cleared Insignis System features a syringe-based, non-electric portable driver, accompanied by a carrying case.
For intravenous medication administration, the Insignis Intravenous (IV) Controller includes a selectable rate flow dial and tubing for direct connection to an IV catheter.
For administering 20% SCIg solutions, the OneSett Subcutaneous Administration Set features a selectable rate flow controller connected to an administration set with configurations of one to four 26-gauge needles.
These needles are designed to reduce pain while delivering the maximum flow rate as specified by the drug manufacturer.
Additionally, IHS offers improved 26-gauge subcutaneous needle sets and the Q-Controller Subcutaneous Administration Set, which is currently available only in the European Union.
